Pfizer (NYSE:PFE) Sets New 1-Year Low at $25.26

Shares of Pfizer Inc. (NYSE:PFE) reached a new 52-week low during mid-day trading on Thursday . The company traded as low as $25.26 and last traded at $25.30, with a volume of 19767977 shares trading hands. The stock had previously closed at $25.42.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Monday, April 15th. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective on the stock. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Trading Up 2.4 %

The firm has a market cap of $147.17 billion, a PE ratio of 72.19, a PEG ratio of 1.14 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The stock’s fifty day simple moving average is $27.11 and its two-hundred day simple moving average is $28.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter in the prior year, the company earned $1.14 earnings per share. The business’s revenue was down 41.3% compared to the same quarter last year. On average, sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Institutional Investors Weigh In On Pfizer

A number of institutional investors have recently made changes to their positions in PFE. Moneta Group Investment Advisors LLC grew its holdings in shares of Pfizer by 89,592.7% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock valued at $8,257,000,000 after buying an additional 160,963,976 shares during the last quarter. Norges Bank bought a new position in Pfizer during the fourth quarter valued at approximately $2,129,927,000. Wellington Management Group LLP lifted its position in Pfizer by 4.9% during the fourth quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock valued at $6,886,849,000 after purchasing an additional 11,099,024 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 10.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock valued at $3,161,261,000 after purchasing an additional 9,393,992 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in Pfizer by 13.8% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock valued at $1,972,300,000 after purchasing an additional 8,298,920 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.